Business Wire

Armis Identifies the Riskiest Assets Introducing Threats to Global Businesses

5.9.2023 16:00:00 EEST | Business Wire | Press release

Share

Armis, the leading asset visibility and security company, today released new research identifying the riskiest connected assets posing threats to global businesses. Findings highlight risk being introduced to organizations through a variety of connected assets across device classes, emphasizing a need for a comprehensive security strategy to protect an organization’s entire attack surface in real-time.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905844605/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Source: Data from the Armis Asset Intelligence Engine collected between August 2022 and July 2023.

“Continuing to educate global businesses about the evolving and increased risk being introduced to their attack surface through managed and unmanaged assets is a key mission of ours,” said Nadir Izrael, CTO and Co-Founder of Armis. “This intelligence is crucial to helping organizations defend against malicious cyberattacks. Without it, business, security and IT leaders are in the dark, vulnerable to blind spots that bad actors will seek to exploit.”

Armis’ research, analyzed from the Armis Asset Intelligence Engine, focuses on connected assets with the most attack attempts, weaponized Common Vulnerabilities and Exposures (CVEs) and high-risk ratings to determine the riskiest assets.

Assets With The Highest Number of Attack Attempts

Armis found the top 10 asset types with the highest number of attack attempts were distributed across asset types: IT, OT, IoT, IoMT, Internet of Personal Things (IoPT) and Building Management Systems (BMS). This demonstrates that attackers care more about their potential access to assets rather than the type, reinforcing the need for security teams to account for all physical and virtual assets as part of their security strategy.

Top 10 device types with the highest number of attack attempts:

  • Engineering workstations (OT)
  • Imaging workstations (IoMT)
  • Media players (IoT)
  • Personal computers (IT)
  • Virtual machines (IT)
  • Uninterruptible power supply (UPS) devices (BMS)
  • Servers (IT)
  • Media writers (IoMT)
  • Tablets (IoPT)
  • Mobile phones (IoPT)

“Malicious actors are intentionally targeting these assets because they are externally accessible, have an expansive and intricate attack surface and known weaponized CVEs,” said Tom Gol, CTO of Research at Armis. “The potential impact of breaching these assets on businesses and their customers is also a critical factor when it comes to why these have the highest number of attack attempts. Engineering workstations can be connected to all controllers in a factory, imaging workstations will collect private patient data from hospitals and UPSs can serve as an access point to critical infrastructure entities, making all of these attractive targets for malicious actors with varying agendas, like deploying ransomware or causing destruction to society in the case of nation-state attacks. IT leaders need to prioritize asset intelligence cybersecurity and apply patches to mitigate this risk.”

Assets With Unpatched, Weaponized CVEs Vulnerable to Exploitation

Researchers identified a significant number of network-connected assets susceptible to unpatched, weaponized CVEs published before 1/1/2022. Zooming in on the highest percentage of devices of each type that had these CVEs between August 2022 and July 2023, Armis identified the list reflected in Figure A. Unpatched, these assets introduce significant risk to businesses.

Assets with a High-Risk Rating

Armis also examined asset types with the most common high-risk factors:

  • Many physical devices on the list that take a long time to replace, such as servers and Programmable Logic Controllers (PLCs), run end-of-life (EOL) or end-of-support (EOS) operating systems. EOL assets are nearing the end of functional life but are still in use, while EOS assets are no longer actively supported or patched for vulnerabilities and security issues by the manufacturer.
  • Some assets, including personal computers, demonstrated SMBv1 usage. SMBv1 is a legacy, unencrypted and complicated protocol with vulnerabilities that have been targeted in the infamous Wannacry and NotPetya attacks. Security experts have advised organizations to stop using it completely. Armis found that 74% of organizations today still have at least one asset in their network vulnerable to EternalBlue – an SMBv1 vulnerability.
  • Many assets identified in the list exhibited high vulnerability scores, have had threats detected, have been flagged for unencrypted traffic or still have the CDPwn vulnerabilities impacting network infrastructure and VoIPs.
  • Half (50%) of pneumatic tube systems were found to have an unsafe software update mechanism.

Additional research from Armis is available on the riskiest OT and ICS devices across critical infrastructure industries as well as the riskiest medical and IoT devices in clinical environments.

Learn more about Armis at www.armis.com.

About Armis

Armis, the leading asset visibility and security company, provides the industry’s first unified asset intelligence platform designed to address the new extended attack surface that connected assets create. Fortune 100 companies trust our real-time and continuous protection to see with full context all managed, unmanaged assets across IT, cloud, IoT devices, medical devices (IoMT), operational technology (OT), industrial control systems (ICS), and 5G. Armis provides passive cyber asset management, risk management, and automated enforcement. Armis is a privately held company and headquartered in California.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye